Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0001295

Spironolactone for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Spironolactone, 4-Pregnen-21-oic acid-17α-ol-3-one-7α-thiol γ-lactone 7-acetate, 7α-(Acetylthio)-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

2.06 MG
MXP 3,257.00

MXP 3,257.00

Check Cart for Availability
Solicitar un pedido a granel
Todas las fotos(1)

Seleccione un Tamaño

Cambiar Vistas
2.06 MG
MXP 3,257.00

About This Item

Fórmula empírica (notación de Hill):
C24H32O4S
Número de CAS:
52-01-7
Peso molecular:
416.57
Número MDL:
MFCD00082250
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329831347
NACRES:
NA.24

MXP 3,257.00

Check Cart for Availability
Solicitar un pedido a granel

grado

pharmaceutical primary standard

familia API

spironolactone

fabricante / nombre comercial

EDQM

mp

207-208 °C (lit.)

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

Clave InChI

LXMSZDCAJNLERA-ZHYRCANASA-N

Información sobre el gen

human ... NR3C2(4306)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Spironolactone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

Spironolactone is a competitive aldosterone receptor antagonist. Used as potassium sparing diuretic.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Pictogramas

Health hazard
GHS08

Palabra de señalización

Danger

Frases de peligro

H351,H360FD,H373

Clasificaciones de peligro

Carc. 2 - Repr. 1B - STOT RE 2

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Julie Brown et al.
The Cochrane database of systematic reviews, (2)(2), CD000194-CD000194 (2009-04-17)
Hirsutism is the presence of excessive hair growth in women and is an important cosmetic condition often resulting in severe distress. The most common cause is by increased production of male sex hormones (androgens). It is also affected by increased
Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?
Andrew S Bomback et al.
Nature clinical practice. Nephrology, 5(2), 74-75 (2008-11-26)
Natalie A Christy et al.
The Annals of pharmacotherapy, 39(9), 1517-1521 (2005-08-04)
To evaluate the level of evidence for treatment of hirsutism associated with polycystic ovary syndrome (PCOS) with spironolactone. Studies and reports were located in MEDLINE (1966-January 2005), EMBASE, and International Pharmaceutical Abstracts through the second week of January 2005. Hirsutism
GianLuca Colussi et al.
Journal of hypertension, 31(1), 3-15 (2012-09-27)
Mineralocorticoid receptor antagonists (MRAs) are commonly used to reduce blood pressure, left-ventricular hypertrophy, and urinary albumin excretion in patients with essential hypertension or primary aldosteronism. Effects of MRAs on hypertensive organ damage seem to occur beyond what is expected from
Allan Struthers et al.
Clinical cardiology, 31(4), 153-158 (2008-04-12)
Improved understanding of the adverse pharmacological properties of aldosterone has prompted investigation of the clinical benefits of blocking aldosterone at the receptor level. This article reviews the pharmacology, clinical efficacy, and tolerability of the two available blocking agents, spironolactone and
Ver todos los artículos relacionados

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico